Please assess the completion status of the following clinical trial:

Trial Title: Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adenocarcinoma~* Unresectable and recurrent gastric cancer~* Age 20 to 74~* Performance status 0, 1, or 2 (ECOG)~* Life expectancy 3 months~* No prior chemotherapy or radiotherapy for gastric cancer~* Able to take oral medication~* Evaluable or not evaluable lesion had already checked more than 28 days before participated in this study~* Hematopoietic Absolute granulocyte count lower limit of normal-12,000/mm\^3 Platelet ≥ 100,000/mm\^3 Hemoglobin ≥ 8.0 g/dL~* Hepatic AST and ALT ≤ 100 U/L ALP ≤ 2 times upper limit of normal (ULN) Bilirubin ≤ 1.5 mg/dL~* Renal Plasma creatinine ≤ ULN Creatinine clearance ≥ 50 mL/min~Exclusion Criteria:~* Pregnant or nursing~* Bleeding from gastrointestinal tract or no diarrhea~* Hypersensitivity to TS-1 or CDDP~* Psychiatric disorder that would preclude study compliance or giving informed consent~* Severe acute or chronic medical or psychiatric condition or laboratory abnormality~* Serious illness or medical condition~* Brain metastasis~* Ascites requiring drainage

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): TS-1 and cisplatin
- 2 (Type: ACTIVE_COMPARATOR): TS-1

Based on this trial design, predict the completion outcome and termination type (if applicable).